Articles from Xaira Therapeutics

Xaira Therapeutics today announced the appointment of Dr. Rachel Lane as Senior Vice President, Business Development and Operations, reporting to President and COO Jeff Jonker. In this role, Dr. Lane will work closely with Jonker and CEO Marc Tessier-Lavigne to oversee the business development strategy, align them with Xaira’s scientific vision and drive partnerships to integrate cutting-edge machine learning with therapeutic development to accelerate the discovery of life-changing medicines.

Xaira Therapeutics, a company built to transform drug discovery through AI, today announced X-Cell, its first virtual cell model. Trained on causal, interventional data at unprecedented scale, X-Cell achieves state-of-the-art performance in accurately predicting the outcomes of genetic perturbations — including experiments the model has never seen. This marks a meaningful step toward transforming drug discovery from a trial-and-error process into a predictive engineering discipline.

Xaira Therapeutics today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira builds the next generation of AI-driven drug discovery. He will be responsible for overseeing all operational functions and aligning them with Xaira’s scientific vision, scaling the organization, and helping integrate cutting-edge machine learning with therapeutic development to accelerate the discovery of life-changing medicines.

Xaira Therapeutics today announced a significant leap forward in developing AI-driven virtual cell models with the release of “X-Atlas/Orion,” the largest publicly available Perturb-seq atlas. This extensive dataset was made possible by Xaira’s concurrently introduced “Fix-Cryopreserve-ScRNAseq” (FiCS) Perturb-seq platform, a highly scalable technology designed for large-scale data generation. These combined advancements are poised to accelerate the development of biological foundation models and unlock new frontiers in biological discovery and therapeutic development.

Xaira Therapeutics today announced the appointment of Dr. Bo Wang as SVP and Head of Biomedical AI. In this role, Dr. Wang will lead the company’s efforts to develop AI-driven models to help elucidate the molecular basis of poorly treated diseases and to match novel treatments to patients most likely to respond – two major challenges of the drug discovery process.

Xaira Therapeutics today announced the appointment of Dr. Paulo Fontoura and Dr. Hetu Kamisetty to its C-suite. Fontoura will serve as chief medical officer effective early 2025, and Kamisetty will serve as chief technology officer effective immediately. Both will report to Xaira CEO Marc Tessier-Lavigne. These two additions further build out the C-suite for Xaira, which includes the recent appointments of Dr. Debbie Law as chief scientific officer and Julia Tran as chief people officer.

Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief scientific officer, and Tran will lead HR efforts as chief people officer. Both will report to Xaira CEO Marc Tessier-Lavigne.

Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched with more than $1 billion of committed capital from lead investors ARCH Venture Partners and Foresite Capital, joined by F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, among others.